Patents Examined by Sean McGarry
  • Heterologous UTR sequences for enhanced mRNA expression
    Patent number: 11980672
    Abstract: mRNAs containing an exogenous open reading frame (ORF) flanked by a 5? untranslated region (UTR) and a 3? UTR is provided, wherein the 5? and 3? UTRs are derived from a naturally abundant mRNA in a tissue. Also provided are methods for identifying the 5? and 3? UTRs, and methods for making and using the mRNAs.
    Type: Grant
    Filed: June 21, 2022
    Date of Patent: May 14, 2024
    Assignee: ModernaTX, Inc.
    Inventors: David H. Burkhardt, Romesh R. Subramanian, Christian Cobaugh
  • Amphiphilic polynucleotides
    Patent number: 11965164
    Abstract: Compositions and methods disclosed herein can help provide improved delivery of non-natural therapeutic nucleotides for the treatment of diseases such as cancer. An example composition includes an assembly of amphiphilic polynucleotides, where each amphiphilic polynucleotide includes an aptamer portion, a first nucleotide portion, and a second nucleotide portion.
    Type: Grant
    Filed: October 31, 2022
    Date of Patent: April 23, 2024
    Assignee: Duke University
    Inventors: Ashutosh Chilkoti, Stefan Zauscher, Lei Tang, Sonal Deshpande
  • Methods and compositions for sensitization of tumor cells to immune therapy
    Patent number: 11965161
    Abstract: Provided herein are methods and compositions related to the treatment or prevention of cancer (e.g., by targeting a tumor in a subject with cancer) by administering to a subject an agent that inhibits autophagy. In certain aspects, provided herein are methods of compositions related to methods of sensitizing cancer cells to tumor necrosis factor-alpha (TNF-?) mediated killing by contacting the cells or administering the agent that inhibits autophagy.
    Type: Grant
    Filed: March 3, 2021
    Date of Patent: April 23, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Tara Young, Christopher Daly, Gavin Thurston
  • Methods and compositions for inhibiting PMP22 expression
    Patent number: 11959080
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting PMP22 expression and for treating, preventing, or ameliorating a disease associated with PMP22.
    Type: Grant
    Filed: October 4, 2021
    Date of Patent: April 16, 2024
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Gene Hung, Holly Kordasiewicz, Hien Thuy Zhao, Eric E. Swayze
  • Staufen1 regulating agents and associated methods
    Patent number: 11946046
    Abstract: Methods of minimizing dysregulation of Staufen1-associated RNA metabolism can include introducing an amount of a Staufen1-regulating agent to a target cell sufficient to minimize the dysregulation. Therapeutic compositions for treating a neurodegenerative condition associated with Staufen1-induced dysregulation of RNA metabolism can include a therapeutically effective amount of a Staufen1-regulating agent and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: April 2, 2024
    Assignee: University of Utah Research Foundation
    Inventors: Stefan M. Pulst, Daniel R. Scoles, Sharan Paul
  • Compositions and therapeutic methods of microRNA gene delivery
    Patent number: 11946064
    Abstract: Described herein are compositions and methods for treating a disease in a subject by administering delivery vectors that express artificial microRNAs, artificial microRNA clusters, and/or a combination of microRNA clusters and associated non-coding RNAs to the subject. Also described herein are methods for preparing artificial microRNAs and artificial microRNA clusters.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: April 2, 2024
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Pierpaolo Peruzzi, Ennio Antonio Chiocca
  • Translatable molecules and synthesis thereof
    Patent number: 11939363
    Abstract: A range of therapeutic mRNA molecules expressible to provide a target polypeptide or protein. The RNA molecules can contain one or more 5-methoxyuridines and 5-methylcytidines. Further provided are DNA templates, which can be transcribed to provide a target mRNA, and can have altered nucleotides, such as reduced deoxyadenosines. Also provided are processes for making the therapeutic mRNA molecules. The RNA molecules can be translated in vitro or in vivo to provide an active polypeptide or protein. The RNA molecules can be included in a composition used for preventing, treating, or ameliorating at least one symptom of a disease or condition in a subject in need thereof.
    Type: Grant
    Filed: July 14, 2022
    Date of Patent: March 26, 2024
    Assignee: ARCTURUS THERAPEUTICS, INC.
    Inventors: Pattraranee Limphong, Kiyoshi Tachikawa, Padmanabh Chivukula, Daiki Matsuda, Arisa Cale
  • Twist signaling inhibitor compositions and methods of using the same
    Patent number: 11926826
    Abstract: The present invention relates to compositions comprising TWIST signaling inhibitors and optionally one or more anti-cancer agents, and methods of using the compositions for the treatment of cancer.
    Type: Grant
    Filed: June 24, 2022
    Date of Patent: March 12, 2024
    Assignees: City of Hope, The Regents of the University of California
    Inventors: Carlotta A. Glackin, John Rossi, Jeffrey I. Zink, Fuyuhiko Tamanoi, Cai M. Roberts, James Finlay
  • Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1
    Patent number: 11926828
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: March 12, 2024
    Assignee: Phio Pharmaceuticals Corp.
    Inventor: Gerard Cauwenbergh
  • Compositions and methods for inhibiting expression of RRM2 genes
    Patent number: 11920134
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a RRM2 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of a RRM2 gene using said pharmaceutical composition; and methods for inhibiting the expression of RRM2 in a cell.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: March 5, 2024
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: John Frederick Boylan, Birgit Bramlage, Markus Hossbach, John Reidhaar-Olson
  • Compositions and methods for the expression of CRISPR guide RNAs using the H1 promoter
    Patent number: 11896679
    Abstract: The presently disclosed subject matter provides compositions and methods for the expression of CRISPR guide RNAs using the H1 promoter. In particular, compositions and methods are provided for the use of the H1 promoter to express CRISPR guide RNA (gRNA) with altered specificity of the 5? nucleotide, as well as use of the H1 promoter sequence as a bidirectional promoter to express Cas9 nuclease and the gRNA simultaneously. Compositions and methods are also provided for the expression and regulation of gRNA expression in vivo through the use of RNA ribozymes and regulatable aptazymes.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: February 13, 2024
    Assignee: The Johns Hopkins University
    Inventors: Vinod Jaskula-Ranga, Donald Zack
  • Aptamers against , compositions comprising aptamers against and methods of using the same
    Patent number: 11898146
    Abstract: Compositions comprising optimized aptamers capable of specifically binding to a surface protein of Clostridium difficile spore are provided. A method for detecting, enriching, separating, and/or isolating Clostridium difficile spores is provided.
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: February 13, 2024
    Assignee: LIV PROCESS, INC.
    Inventors: Ronald J. Shannon, Gregory Penner
  • Methods for treating multiple sclerosis using antisense oligonucleotides
    Patent number: 11891606
    Abstract: A method for treating a patient suffering from multiple sclerosis, including progressive forms of multiple sclerosis, comprising periodically administering a pharmaceutical composition comprising a therapeutically effective amount of OLIGONUCLEOTIDE I to the patient, thereby treating the patient.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: February 6, 2024
    Assignee: Antisense Therapeutics Ltd
    Inventor: George Tachas
  • Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors
    Patent number: 11891607
    Abstract: The present disclosure provides methods of treating a subject having decreased bone mineral density or at risk of developing decreased bone mineral density, and methods of identifying subjects having an increased risk of developing decreased bone mineral density.
    Type: Grant
    Filed: July 29, 2022
    Date of Patent: February 6, 2024
    Assignees: Regeneron Pharmaceuticals, Inc., The Royal Institution For the Advancement of Learning/McGill University
    Inventors: Jonas Bovijn, Olukayode Sosina, Sirui Zhou, Luca Andrea Lotta, Aris Baras, John Brent Richards
  • Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
    Patent number: 11866709
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.
    Type: Grant
    Filed: November 22, 2021
    Date of Patent: January 9, 2024
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Brian Bettencourt, William Querbes, Kevin Fitzgerald, Maria Frank-Kamenetsky, Stuart Milstein, Svetlana Shulga Morskaya
  • Exonic splicing enhancers and exonic splicing silencers
    Patent number: 11866784
    Abstract: Compounds and methods for regulation of exonic splicing enhancers and exonic splicing silencers. Compounds include polynucleotides targeted to aberrant exonic splicing enhancers and exonic splicing silencers. Compounds and methods for the diagnosis of diseases and conditions associated with aberrant exonic splicing enhancers and exonic splicing silencers. Methods for identifying splicing-sensitive disease mutations, and functional RNA elements as targets for amelioration of aberrant pre-mRNA splicing.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: January 9, 2024
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Jeremy Sanford, Timothy Steme-Weiler
  • Aptamers for personal health care applications
    Patent number: 11859187
    Abstract: An aptamer composition is disclosed which has one or more oligonucleotides that include at least one of deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, or mixtures thereof. The aptamer composition has a binding affinity for one or more cellular membrane glycoproteins selected from the group consisting of: intercellular adhesion molecule 1 (ICAM-1), low-density lipoprotein receptor (LDLR) family members, and cadherin-related family member 3 (CDHR3), preferably intercellular adhesion molecule 1 (ICAM-1), and is configured to reduce the binding of one or more human rhinoviruses to the intercellular adhesion molecule 1 (ICAM-1).
    Type: Grant
    Filed: June 24, 2021
    Date of Patent: January 2, 2024
    Assignee: The Procter & Gamble Company
    Inventors: Juan Esteban Velasquez, Spencer Christopher Rupard, Amy Violet Trejo, Adam Michael Pitz, Kelly Lee Schmeichel, Erin Nicole Swigart, Gregory Allen Penner
  • Compositions and methods for the expression of CRISPR guide RNAs using the H1 promoter
    Patent number: 11850289
    Abstract: The presently disclosed subject matter provides compositions and methods for the expression of CRISPR guide RNAs using the H1 promoter. In particular, compositions and methods are provided for the use of the H1 promoter to express CRISPR guide RNA (gRNA) with altered specificity of the 5? nucleotide, as well as use of the H1 promoter sequence as a bidirectional promoter to express Cas9 nuclease and the gRNA simultaneously. Compositions and methods are also provided for the expression and regulation of gRNA expression in vivo through the use of RNA ribozymes and regulatable aptazymes.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: December 26, 2023
    Assignee: The Johns Hopkins University
    Inventors: Vinod Jaskula-Ranga, Donald Zack
  • DNA monoclonal antibodies targeting influenza virus
    Patent number: 11851477
    Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an anti-influenza-hemagglutinin synthetic antibody. The disclosure also provides a method of preventing and/or treating influenza in a subject using said composition and method of generation.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: December 26, 2023
    Assignees: The Trustees of the University of Pennsylvania, The Wistar Institute of Anatomy and Biology, Inovio Pharmaceuticals, Inc.
    Inventors: David B. Weiner, Ami Patel, Jian Yan, Sarah Elliott
  • Models of tauopathy
    Patent number: 11845957
    Abstract: BANF1, PPP2CA, and ANKLE2 were identified as genes that promote tau aggregation when disrupted. Improved tauopathy models such as cells, tissues, or animals having mutations in or inhibition of expression of BANF1 and/or PPP2CA and/or ANKLE2 are provided. Methods of using such improved tauopathy models for assessing therapeutic candidates for the treatment of a tauopathy, methods of making the improved tauopathy models, and methods of accelerating or exacerbating tau aggregation in a tauopathy model are also provided.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: December 19, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Marine Prissette, Matthew Koss, Mathieu Desclaux, John McWhirter, Arijit Bhowmick, David Frendewey, Brian Zambrowicz, Claudia Racioppi